Results 81 to 90 of about 171,701 (311)

Voclosporin‐induced gingival enlargement: A case report

open access: yesClinical Advances in Periodontics, EarlyView.
Abstract Background Drug‐influenced gingival enlargement (DIGE) is a recognized adverse effect of certain medications, particularly immunosuppressants like cyclosporin and tacrolimus. However, there have been no documented cases of DIGE associated with voclosporin, a newer calcineurin inhibitor used primarily to treat lupus nephritis.
Francesca Racca   +2 more
wiley   +1 more source

Tolerated or Celebrated? Black Men in Doctoral Counselor Education Programs

open access: yesCounselor Education and Supervision, EarlyView.
ABSTRACT Black students face more difficulties when it comes to gaining doctoral degrees compared to other races. However, not enough is known about Black men in doctoral counselor education (CE) programs. Using interpretive phenomenological analysis and guided by Black Critical Theory, we explored the lived experiences of 10 Black men in doctoral CE ...
Demetrius Cofield   +2 more
wiley   +1 more source

Rubrolides A, D, P, T, U: Total Syntheses and Antibacterial Evaluation of Highly Brominated Marine Natural Products

open access: yesChemistryEurope, EarlyView.
Following the Danube Flow. The first total syntheses of highly brominated rubrolides T, U, and U‐analog, together with the efficient and divergent syntheses of rubrolides A, D, and P. The dibrominated key intermediate, obtained via a Suzuki‐Miyaura cross‐coupling reaction, is the centerpiece of the synthesis.
Jasmin Janneschütz   +7 more
wiley   +1 more source

Caffeine Content Assessment in Beverages and Food Supplements: Regulatory Challenges and Health Implications

open access: yesChemFoodChem, EarlyView.
ABSTRACT This study presents an analysis of caffeine content in food supplements and evaluates current regulatory frameworks against established safety guidelines. High‐caffeine products, particularly sports, and food supplements, were assessed for compliance with the safety opinion of the European Food Safety Authority (EFSA). The investigation during
Leonie Rinke   +3 more
wiley   +1 more source

Assessment and management of chronic insomnia disorder: an algorithm for primary care physicians

open access: yesBMC Primary Care
Background Primary care physicians often lack resources and training to correctly diagnose and manage chronic insomnia disorder. Tools supporting chronic insomnia diagnosis and management could fill this critical gap. A survey was conducted to understand
Hugh Selsick   +8 more
doaj   +1 more source

Optimal model‐based design of experiments for parameter precision: Supercritical extraction case

open access: yesThe Canadian Journal of Chemical Engineering, EarlyView.
Abstract This study investigates the process of chamomile oil extraction from flowers. A parameter‐distributed model consisting of a set of partial differential equations is used to describe the governing mass transfer phenomena in a cylindrical packed bed with solid chamomile particles under supercritical conditions using carbon dioxide as a solvent ...
Oliwer Sliczniuk, Pekka Oinas
wiley   +1 more source

Insomnia remission and improvement of bodily pain in older adults: a randomized clinical trial

open access: yesPAIN Reports
. Introduction:. Older adults with insomnia frequently report bothersome pain. Whether insomnia treatment reduces bodily pain in older adults without chronic pain conditions is not known. Objectives:.
Martin F. Bjurstrom   +2 more
doaj   +1 more source

A Phase 1, Randomized, Placebo‐Controlled, Multiple‐Dose, Double‐Blind Study to Evaluate and Compare the Pharmacokinetics and Safety of Rimegepant in Healthy Adult Japanese and Caucasian Individuals

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract This Phase 1, randomized, placebo‐controlled, double‐blind study assessed the pharmacokinetic profile of rimegepant (25, 75, or 150 mg once daily for 14 days) in healthy Japanese and Caucasian adults. Exposures were modestly increased in Japanese participants compared with Caucasian participants following a single dose of rimegepant (Day 1 ...
Rajinder Bhardwaj   +6 more
wiley   +1 more source

Quantitative Systems Toxicology Modeling with DILIsym to Support Phase 3 Dose Selection for Fezolinetant

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Fezolinetant is a first‐in‐class, selective, non‐hormonal, neurokinin 3 receptor antagonist that is approved for the treatment of moderate to severe vasomotor symptoms due to menopause. In a phase 2b clinical study (n = 352), nine study participants experienced elevations in serum transaminases exceeding three times the upper limit of normal.
Jace C. Nielsen   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy